Marcelo Galarza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marcelo Galarza has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Gazzeri
Department of Neurosurgery, San Giovanni-Addolorata Hospital, Rome, Italy
7 shared publications - Felice Occhigrossi
Interventional and Surgical Pain Management Unit, San Giovanni–Addolorata Hospital, Via Amba Aradam 9, 00184 Rome, Italy
4 shared publications - Roberto Gazzeri
Interventional and Surgical Pain Management Unit, San Giovanni–Addolorata Hospital, Via Amba Aradam 9, 00184 Rome, Italy
4 shared publications Claudio Fiore
Department of Neurosurgery, San Giovanni Addolorata Hospital, Rome, Italy
3 shared publications- Jacopo Mosca
Anesthesiology, Critical Care and Pain Medicine, La Sapienza University of Rome, 00185 Rome, Italy
3 shared publications Massimiliano Neroni
3 shared publications
Latest Publications
- Open Access
Fibrillar Cellulose-Based Hemostatic Agents for Intraoperative Bleeding Control: A Comparative Analysis of the Physical and Chemical Properties
Background: The selection of the optimal hemostatic agent for surgical procedures remains a subject of ongoing debate. Among topical hemostatic agents, cellulose-based hemostats constitute a significant class of biocompatible and bioabsorbable polymers, widely recognized for their superior performance and broad range of medical applications. Fibrillar cellulose-based hemostatic agents, derived from natural plant sources, enhance platelet adhesion and play a critical role in hemostasis by activating both the intrinsic and extrinsic clotting cascades; they differ significantly in their physical structure, handling characteristics, and best clinical application from the classical cellulose-based hemostatic agents. Their versatility and efficacy have led to widespread use across various surgical specialties. Methods: This study aimed to compare the physicochemical properties of three commercially available fibrillar oxidized regenerated cellulose (ORC) hemostatic agents. Specifically, key parameters influencing their clinical performance, such as swelling capacity, degradation rate, absorption capacity, and pH levels, were evaluated. Additionally, expert assessments were conducted to analyze the intraoperative handling properties of these agents during surgical procedures. Results: The findings revealed that operative handling scores were broadly comparable among the three products tested, as all fibrillar ORC hemostats readily conformed to irregularly shaped cavities and adhered well to the application site. However, differences were observed in their swelling, pH, absorption, and dissolution properties. Surgicel Fibrillar showed the lowest swelling (25%, vs. 40% for Pahacel Fibril and 65% for Equitamp Fibrillar) and the lowest pH values, and was completely dissolved in vitro by day 7, whereas Pahacel Fibril and Equitamp Fibrillar remained visible at day 31; Pahacel Fibril absorbed the test solution more slowly than the other two products. Conclusions: These in vitro results provide information on the physicochemical and handling characteristics of three fibrillar ORC hemostatic agents, including their swelling, absorption, pH, and dissolution behavior, which may be relevant to product selection. Differences in physical properties should not be interpreted as differences in clinical hemostatic efficacy, which was not assessed in this study.
Open AccessFibrillar Cellulose-Based Hemostatic Agents for Intraoperative Bleeding Control: A Comparative Analysis of the Physical and Chemical Properties
Background: The selection of the optimal hemostatic agent for surgical procedures remains a subject of ongoing debate. Among topical hemostatic agents, cellulose-based hemostats constitute a significant class of biocompatible and bioabsorbable polymers, widely recognized for their superior performance and broad range of medical applications. Fibrillar cellulose-based hemostatic agents, derived from natural plant sources, enhance platelet adhesion and play a critical role in hemostasis by activating both the intrinsic and extrinsic clotting cascades; they differ significantly in their physical structure, handling characteristics, and best clinical application from the classical cellulose-based hemostatic agents. Their versatility and efficacy have led to widespread use across various surgical specialties. Methods: This study aimed to compare the physicochemical properties of three commercially available fibrillar oxidized regenerated cellulose (ORC) hemostatic agents. Specifically, key parameters influencing their clinical performance, such as swelling capacity, degradation rate, absorption capacity, and pH levels, were evaluated. Additionally, expert assessments were conducted to analyze the intraoperative handling properties of these agents during surgical procedures. Results: The findings revealed that operative handling scores were broadly comparable among the three products tested, as all fibrillar ORC hemostats readily conformed to irregularly shaped cavities and adhered well to the application site. However, differences were observed in their swelling, pH, absorption, and dissolution properties. Surgicel Fibrillar showed the lowest swelling (25%, vs. 40% for Pahacel Fibril and 65% for Equitamp Fibrillar) and the lowest pH values, and was completely dissolved in vitro by day 7, whereas Pahacel Fibril and Equitamp Fibrillar remained visible at day 31; Pahacel Fibril absorbed the test solution more slowly than the other two products. Conclusions: These in vitro results provide information on the physicochemical and handling characteristics of three fibrillar ORC hemostatic agents, including their swelling, absorption, pH, and dissolution behavior, which may be relevant to product selection. Differences in physical properties should not be interpreted as differences in clinical hemostatic efficacy, which was not assessed in this study.
- Open Access
- 3 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5206
Oral Food Supplement with Bio-Activated Silicium and Vitamins D3 and K2 in the Conservative Management of Osteoporotic Vertebral Compression Fractures
Background: Osteoporotic vertebral compression fractures (OVCFs) are the most prevalent manifestation of osteoporotic skeletal disease, associated with severe pain, functional decline, and elevated risk of subsequent fractures. Conservative management remains the first-line approach for stable fractures, yet pain control is often suboptimal, and vertebral collapse progresses in up to 37% of patients. Bio-activated orthosilicic acid combined with vitamins D3 and K2 (BioSi-DK) may support fracture healing through complementary mechanisms acting on osteoblast differentiation, collagen synthesis, osteocalcin carboxylation, and mineralization, but its clinical efficacy in OVCFs has not previously been investigated. Methods: A retrospective, multi-center comparative cohort study was conducted in patients aged >50 years with DXA-confirmed osteoporosis and acute thoracolumbar OVCFs (AO Spine OF1-OF2) managed conservatively. Patients receiving BioSi-DK supplementation (two capsules daily for two months, then one capsule daily for four months) in addition to standard conservative treatment were compared with controls receiving conservative treatment alone. Propensity score matching (1:1, sex-exact constraint, caliper 0.3 SD) was applied across twelve pre-specified baseline covariates. The primary outcome was pain intensity at six months, assessed by numerical rating scale (NRS). Secondary outcomes included NRS change, analgesic use, Patient Global Impression of Change (PGIC), requirement for vertebral augmentation (kyphoplasty), MRI marrow edema score (MES), and Genant grade change. Results: After propensity score matching, 38 patients (19 per group) with balanced baseline characteristics were analyzed (mean age 71.2 ± 6.5 years; 89.5% female; mean T-score −2.61 ± 0.32; mean baseline NRS 8.26 ± 0.95). The BioSi-DK group achieved a significantly lower post-treatment NRS score compared with controls (2.05 ± 2.17 vs. 3.84 ± 2.83; p = 0.015; Cohen’s d = −0.71) and a significantly greater mean NRS reduction (−6.21 ± 1.90 vs. −4.42 ± 2.12 points; p = 0.005; d = −0.89). Analgesic discontinuation was more frequent in the BioSi-DK group (68.4% vs. 36.8%; p = 0.068). Kyphoplasty was required in 5.3% of BioSi-DK patients versus 21.1% of controls (p = 0.340; OR = 0.21), and vertebral compression grade remained stable in 100% of supplemented patients versus 84% of controls. At two months, MES improvement by at least one category was more frequently observed in the BioSi-DK group than in controls, suggesting an earlier edema resolution effect; at six months, MES distribution was comparable between groups (p = 0.620). Conclusions: BioSi-DK supplementation as an adjunct to conservative management was associated with a statistically significant and clinically large reduction in pain at six months, with favorable trends in analgesic burden, kyphoplasty requirement, and edema resolution. The safety profile was excellent. These findings support the conduct of prospective, randomized, placebo-controlled trials to confirm BioSi-DK as an effective adjunct therapy for OVCFs.
- 3 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5206
Open AccessOral Food Supplement with Bio-Activated Silicium and Vitamins D3 and K2 in the Conservative Management of Osteoporotic Vertebral Compression Fractures
Background: Osteoporotic vertebral compression fractures (OVCFs) are the most prevalent manifestation of osteoporotic skeletal disease, associated with severe pain, functional decline, and elevated risk of subsequent fractures. Conservative management remains the first-line approach for stable fractures, yet pain control is often suboptimal, and vertebral collapse progresses in up to 37% of patients. Bio-activated orthosilicic acid combined with vitamins D3 and K2 (BioSi-DK) may support fracture healing through complementary mechanisms acting on osteoblast differentiation, collagen synthesis, osteocalcin carboxylation, and mineralization, but its clinical efficacy in OVCFs has not previously been investigated. Methods: A retrospective, multi-center comparative cohort study was conducted in patients aged >50 years with DXA-confirmed osteoporosis and acute thoracolumbar OVCFs (AO Spine OF1-OF2) managed conservatively. Patients receiving BioSi-DK supplementation (two capsules daily for two months, then one capsule daily for four months) in addition to standard conservative treatment were compared with controls receiving conservative treatment alone. Propensity score matching (1:1, sex-exact constraint, caliper 0.3 SD) was applied across twelve pre-specified baseline covariates. The primary outcome was pain intensity at six months, assessed by numerical rating scale (NRS). Secondary outcomes included NRS change, analgesic use, Patient Global Impression of Change (PGIC), requirement for vertebral augmentation (kyphoplasty), MRI marrow edema score (MES), and Genant grade change. Results: After propensity score matching, 38 patients (19 per group) with balanced baseline characteristics were analyzed (mean age 71.2 ± 6.5 years; 89.5% female; mean T-score −2.61 ± 0.32; mean baseline NRS 8.26 ± 0.95). The BioSi-DK group achieved a significantly lower post-treatment NRS score compared with controls (2.05 ± 2.17 vs. 3.84 ± 2.83; p = 0.015; Cohen’s d = −0.71) and a significantly greater mean NRS reduction (−6.21 ± 1.90 vs. −4.42 ± 2.12 points; p = 0.005; d = −0.89). Analgesic discontinuation was more frequent in the BioSi-DK group (68.4% vs. 36.8%; p = 0.068). Kyphoplasty was required in 5.3% of BioSi-DK patients versus 21.1% of controls (p = 0.340; OR = 0.21), and vertebral compression grade remained stable in 100% of supplemented patients versus 84% of controls. At two months, MES improvement by at least one category was more frequently observed in the BioSi-DK group than in controls, suggesting an earlier edema resolution effect; at six months, MES distribution was comparable between groups (p = 0.620). Conclusions: BioSi-DK supplementation as an adjunct to conservative management was associated with a statistically significant and clinically large reduction in pain at six months, with favorable trends in analgesic burden, kyphoplasty requirement, and edema resolution. The safety profile was excellent. These findings support the conduct of prospective, randomized, placebo-controlled trials to confirm BioSi-DK as an effective adjunct therapy for OVCFs.
- Open Access
- 12 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 3063
Spinal Cord Stimulation in Painful Diabetic Neuropathy: Advances, Outcomes, and Future Directions
Painful diabetic neuropathy (PDN) is a common complication of diabetes mellitus, often inadequately managed by conventional pharmacological therapies. Alternative interventions, including spinal cord stimulation (SCS), have garnered increasing attention for their potential effectiveness. This narrative review evaluates the efficacy, safety, mechanisms of action, and impact on quality of life of SCS in the management of PDN. A systematic search was conducted covering the last 15 years (from January 2010 to April 2025), using the keywords “diabetic neuropathy,” “spinal cord stimulation,” “neuropathic pain,” and “neuromodulation” with Boolean operators. Eligible studies included randomized controlled trials (RCTs), observational studies, systematic reviews, and meta-analyses involving adult populations and published in English. Study selection and data extraction were performed independently by two authors. Multiple RCTs and observational studies (involving over 500 patients) were identified. RCTs consistently demonstrated that SCS significantly reduces neuropathic pain intensity compared to conventional medical therapy (CMT). The most recent study, with the largest sample size (216 patients), reported that high-frequency SCS achieved ≥50% pain relief in 79% of patients at 6 months, compared to only 5% in the CMT group. Observational studies confirmed sustained pain relief (≥50% reduction) in approximately 55–80% of patients over 5–10 years. Significant improvements in sleep, neurological function, and quality of life were also consistently observed. The complication rate was low, with infections requiring explantation in approximately 2–3% of cases. Rare serious adverse events, such as spinal hematoma, were reported. Current evidence underlines the efficacy and safety of SCS, particularly newer waveform paradigms, for the treatment of PDN refractory to medical management. Given its durable effects on pain relief, functional improvement, and quality of life, SCS should be considered an option within the treatment algorithm for carefully selected patients with severe, refractory PDN.
- 12 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 3063
Open AccessSpinal Cord Stimulation in Painful Diabetic Neuropathy: Advances, Outcomes, and Future Directions
Painful diabetic neuropathy (PDN) is a common complication of diabetes mellitus, often inadequately managed by conventional pharmacological therapies. Alternative interventions, including spinal cord stimulation (SCS), have garnered increasing attention for their potential effectiveness. This narrative review evaluates the efficacy, safety, mechanisms of action, and impact on quality of life of SCS in the management of PDN. A systematic search was conducted covering the last 15 years (from January 2010 to April 2025), using the keywords “diabetic neuropathy,” “spinal cord stimulation,” “neuropathic pain,” and “neuromodulation” with Boolean operators. Eligible studies included randomized controlled trials (RCTs), observational studies, systematic reviews, and meta-analyses involving adult populations and published in English. Study selection and data extraction were performed independently by two authors. Multiple RCTs and observational studies (involving over 500 patients) were identified. RCTs consistently demonstrated that SCS significantly reduces neuropathic pain intensity compared to conventional medical therapy (CMT). The most recent study, with the largest sample size (216 patients), reported that high-frequency SCS achieved ≥50% pain relief in 79% of patients at 6 months, compared to only 5% in the CMT group. Observational studies confirmed sustained pain relief (≥50% reduction) in approximately 55–80% of patients over 5–10 years. Significant improvements in sleep, neurological function, and quality of life were also consistently observed. The complication rate was low, with infections requiring explantation in approximately 2–3% of cases. Rare serious adverse events, such as spinal hematoma, were reported. Current evidence underlines the efficacy and safety of SCS, particularly newer waveform paradigms, for the treatment of PDN refractory to medical management. Given its durable effects on pain relief, functional improvement, and quality of life, SCS should be considered an option within the treatment algorithm for carefully selected patients with severe, refractory PDN.
- Open Access
- 20 January 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (1) , 33
Spinal Cord Stimulation for Refractory Angina Pectoris: Current Status and Future Perspectives, a Narrative Review
Refractory angina pectoris (RAP) is a clinical syndrome characterized by persistent chest pain caused by myocardial ischemia that is unresponsive to optimal pharmacological therapy and revascularization procedures. Spinal cord stimulation (SCS) has emerged as a promising therapeutic option for managing RAP, offering significant symptom relief and improved quality of life. A systematic literature review was conducted to evaluate the clinical effectiveness, mechanisms of action, and safety profile of SCS in treating RAP. Comprehensive searches were performed in PubMed, Scopus, and Web of Science for studies published between 1990 and 2023. Of 328 articles identified, 6 met the inclusion and exclusion criteria for final analysis. The included studies consistently demonstrated that SCS significantly reduces the frequency of anginal episodes and nitroglycerin use while improving exercise capacity and quality of life. Proposed mechanisms include modulation of pain signals via the gate control theory, enhancement of autonomic balance, and redistribution of myocardial perfusion. Novel stimulation modalities, including high-frequency, Burst, and Differential Target Multiplexed (DTM), show potential advantages in enhancing patient comfort and clinical outcomes. Nevertheless, long-term studies are necessary to validate these findings and establish the comparative efficacy of these advanced technologies. SCS is a safe and effective therapy for patients with RAP who are unsuitable for surgical interventions. Innovations in neurostimulation, including closed-loop systems and personalized treatment strategies have the potential to further optimize outcomes. Rigorous clinical trials are needed to consolidate the role of SCS as a cornerstone therapy for the management of RAP.
- 20 January 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (1) , 33
Open AccessSpinal Cord Stimulation for Refractory Angina Pectoris: Current Status and Future Perspectives, a Narrative Review
Refractory angina pectoris (RAP) is a clinical syndrome characterized by persistent chest pain caused by myocardial ischemia that is unresponsive to optimal pharmacological therapy and revascularization procedures. Spinal cord stimulation (SCS) has emerged as a promising therapeutic option for managing RAP, offering significant symptom relief and improved quality of life. A systematic literature review was conducted to evaluate the clinical effectiveness, mechanisms of action, and safety profile of SCS in treating RAP. Comprehensive searches were performed in PubMed, Scopus, and Web of Science for studies published between 1990 and 2023. Of 328 articles identified, 6 met the inclusion and exclusion criteria for final analysis. The included studies consistently demonstrated that SCS significantly reduces the frequency of anginal episodes and nitroglycerin use while improving exercise capacity and quality of life. Proposed mechanisms include modulation of pain signals via the gate control theory, enhancement of autonomic balance, and redistribution of myocardial perfusion. Novel stimulation modalities, including high-frequency, Burst, and Differential Target Multiplexed (DTM), show potential advantages in enhancing patient comfort and clinical outcomes. Nevertheless, long-term studies are necessary to validate these findings and establish the comparative efficacy of these advanced technologies. SCS is a safe and effective therapy for patients with RAP who are unsuitable for surgical interventions. Innovations in neurostimulation, including closed-loop systems and personalized treatment strategies have the potential to further optimize outcomes. Rigorous clinical trials are needed to consolidate the role of SCS as a cornerstone therapy for the management of RAP.
- 1 May 2015
- Vol. 26, 364-9
Role of EVICEL Fibrin Sealant to Assist Hemostasis in Cranial and Spinal Epidural Space: A Neurosurgical Clinical Study.
A variety of techniques have been used to stop venous bleeding from the cranial and spinal epidural space. These generally consist of packing with oxidized regenerated cellulose, fibrillar collagen, and so forth, and in cranial surgery, tack-up sutures. Bipolar coagulation may also be used to control bleeding from spinal venous plexus, but it may bear the risk of healthy nervous tissue injury: dissipation of heat from the tips of the bipolar forceps may induce thermal injury to adjacent neural structures. Quick and safe hemostasis reduces the duration of surgery. Efficient control of bleeding is also a prerequisite for the realization of the planned therapeutic procedure, that is, the result of surgery, and can thereby reduce perioperative morbidity. Fibrin sealant is safely used to increase hemostasis and to treat cerebrospinal leakage. Between January 2014 and March 2015, the authors used injection of fibrin sealant (EVICEL®, Johnson & Johnson Wound Management, Somerville, NJ) into the cranial and spinal epidural space to assist in hemostasis in 97 patients. EVICEL injection was used in 81 cases of cranial surgery and 16 cases of spinal surgery. When the venous bleeding continued from the epidural space after packing with classical hemostatic agents, fibrin sealant was used to stop venous bleeding. When arterial bleeding was present, fibrin sealant was not used. In all cases, the results were judged to be excellent with stoppage of epidural bleeding, or good with mild persistent oozing. During the 10-minute observation period, no patients treated with EVICEL required additional hemostatic measures. No complications related to the fibrin glue were encountered.
- 1 May 2015
- Vol. 26, 364-9
Role of EVICEL Fibrin Sealant to Assist Hemostasis in Cranial and Spinal Epidural Space: A Neurosurgical Clinical Study.
A variety of techniques have been used to stop venous bleeding from the cranial and spinal epidural space. These generally consist of packing with oxidized regenerated cellulose, fibrillar collagen, and so forth, and in cranial surgery, tack-up sutures. Bipolar coagulation may also be used to control bleeding from spinal venous plexus, but it may bear the risk of healthy nervous tissue injury: dissipation of heat from the tips of the bipolar forceps may induce thermal injury to adjacent neural structures. Quick and safe hemostasis reduces the duration of surgery. Efficient control of bleeding is also a prerequisite for the realization of the planned therapeutic procedure, that is, the result of surgery, and can thereby reduce perioperative morbidity. Fibrin sealant is safely used to increase hemostasis and to treat cerebrospinal leakage. Between January 2014 and March 2015, the authors used injection of fibrin sealant (EVICEL®, Johnson & Johnson Wound Management, Somerville, NJ) into the cranial and spinal epidural space to assist in hemostasis in 97 patients. EVICEL injection was used in 81 cases of cranial surgery and 16 cases of spinal surgery. When the venous bleeding continued from the epidural space after packing with classical hemostatic agents, fibrin sealant was used to stop venous bleeding. When arterial bleeding was present, fibrin sealant was not used. In all cases, the results were judged to be excellent with stoppage of epidural bleeding, or good with mild persistent oozing. During the 10-minute observation period, no patients treated with EVICEL required additional hemostatic measures. No complications related to the fibrin glue were encountered.
- 1 May 2015
- Vol. 26, 376-81
A Clinico-pathologic Study of Oxidized Cellulose as Topical Hemostatic Agent in Neurosurgery.
Hemostasis is extremely important in neurosurgical procedures to prevent major postoperative bleedings and their catastrophic consequences. Emoxicel TAF Retilight (Bioster, a.s., Czech Republic) is a sterile, resorbable, hemostatic reticulum, mainly used to stop capillary and venous bleeding. The textile form of the hemostatic material allows, in several cases, perfect adjustment to the varied shape of the surgical cavities and of the epidural space to which it adheres when wet. Hemostatic effect is rapid, and complete hemostasis can be achieved in several minutes after application. This topical hemostatic agent is biocompatible, biodegradable, and highly resorbable. It has a hemostatic and antimicrobic effect. The main aim of this study was to verify the efficacy, broadness of use, and safety of this topical hemostatic in neurosurgical procedures. A total of 43 cases were included, 18 cranial and 25 spinal, and in only one case a postoperative epidural bleeding was reported. A histopathologic study of the hemostatic was performed. No allergic reactions were reported. Emoxicel was useful not only in stopping minor bleeding, but also for bleeding prevention in the postoperative period.
- 1 May 2015
- Vol. 26, 376-81
A Clinico-pathologic Study of Oxidized Cellulose as Topical Hemostatic Agent in Neurosurgery.
Hemostasis is extremely important in neurosurgical procedures to prevent major postoperative bleedings and their catastrophic consequences. Emoxicel TAF Retilight (Bioster, a.s., Czech Republic) is a sterile, resorbable, hemostatic reticulum, mainly used to stop capillary and venous bleeding. The textile form of the hemostatic material allows, in several cases, perfect adjustment to the varied shape of the surgical cavities and of the epidural space to which it adheres when wet. Hemostatic effect is rapid, and complete hemostasis can be achieved in several minutes after application. This topical hemostatic agent is biocompatible, biodegradable, and highly resorbable. It has a hemostatic and antimicrobic effect. The main aim of this study was to verify the efficacy, broadness of use, and safety of this topical hemostatic in neurosurgical procedures. A total of 43 cases were included, 18 cranial and 25 spinal, and in only one case a postoperative epidural bleeding was reported. A histopathologic study of the hemostatic was performed. No allergic reactions were reported. Emoxicel was useful not only in stopping minor bleeding, but also for bleeding prevention in the postoperative period.
- 17 February 2015
- Published by Springer Nature in Child's Nervous System
- Vol. 31 (6) , 873-884
Basic cerebrospinal fluid flow patterns in ventricular catheters prototypes
A previous study by computational fluid dynamics (CFD) of the three-dimensional (3-D) flow in ventricular catheters (VC) disclosed that most of the total fluid mass flows through the catheter’s most proximal holes in commercially available VC. The aim of the present study is to investigate basic flow patterns in VC prototypes. The general procedure for the development of a CFD model calls for transforming the physical dimensions of the system to be studied into a virtual wire-frame model which provides the coordinates for the virtual space of a CFD mesh, in this case, a VC. The incompressible Navier–Stokes equations, a system of strongly coupled, nonlinear, partial differential conservation equations governing the motion of the flow field, are then solved numerically. New designs of VC, e.g., with novel hole configurations, can then be readily modeled, and the corresponding flow pattern computed in an automated way. Specially modified VCs were used for benchmark experimental testing. Three distinct types of flow pattern in prototype models of VC were obtained by varying specific parameters of the catheter design, like the number of holes in the drainage segments and the distance between them. Specifically, we show how to equalize and reverse the flow pattern through the different VC drainage segments by choosing appropriate parameters. The flow pattern in prototype catheters is determined by the number of holes, the hole diameter, the ratio hole/segment, and the distance between hole segments. The application of basic design principles of VC may help to develop new catheters with better flow circulation, thus reducing the possibility of becoming occluded.
- 17 February 2015
- Published by Springer Nature in Child's Nervous System
- Vol. 31 (6) , 873-884
Basic cerebrospinal fluid flow patterns in ventricular catheters prototypes
A previous study by computational fluid dynamics (CFD) of the three-dimensional (3-D) flow in ventricular catheters (VC) disclosed that most of the total fluid mass flows through the catheter’s most proximal holes in commercially available VC. The aim of the present study is to investigate basic flow patterns in VC prototypes. The general procedure for the development of a CFD model calls for transforming the physical dimensions of the system to be studied into a virtual wire-frame model which provides the coordinates for the virtual space of a CFD mesh, in this case, a VC. The incompressible Navier–Stokes equations, a system of strongly coupled, nonlinear, partial differential conservation equations governing the motion of the flow field, are then solved numerically. New designs of VC, e.g., with novel hole configurations, can then be readily modeled, and the corresponding flow pattern computed in an automated way. Specially modified VCs were used for benchmark experimental testing. Three distinct types of flow pattern in prototype models of VC were obtained by varying specific parameters of the catheter design, like the number of holes in the drainage segments and the distance between them. Specifically, we show how to equalize and reverse the flow pattern through the different VC drainage segments by choosing appropriate parameters. The flow pattern in prototype catheters is determined by the number of holes, the hole diameter, the ratio hole/segment, and the distance between hole segments. The application of basic design principles of VC may help to develop new catheters with better flow circulation, thus reducing the possibility of becoming occluded.
- 1 November 2014
- Vol. 25, 265-70
(EVICEL) for Augmentation of Dural Closure: Results of a Preliminary Clinical Study.
The authors prospectively evaluated the safety and efficacy of a new fibrin sealant in patients undergoing emergency and elective cranial/spinal surgery with documented cerebrospinal fluid (CSF) leakage after sutured dural repair. This study was designed as a prospective, nonrandomized clinical trial. EVICEL® Fibrin Sealant (Johnson & Johnson, Somerville, NJ) was used in 72 patients with documented intraoperative CSF leakage after neurosurgical dural repair for a variety of pathologies. Intraoperative CSF leakage was either spontaneous or induced by a Valsalva maneuver. Patients were monitored for 1 month postoperatively with physical examinations, clinical laboratory analyses, and diagnostic imaging (CT or MRI). The sealant was effective in closing intraoperative CSF leakage in all patients but one. There were no sealant-related adverse events, and all clinical outcomes were consistent with expectations for seriously ill patients undergoing prolonged neurosurgical procedures. EVICEL® Fibrin Sealant provides a safe and effective watertight closure when used as an adjunct to sutured dural repair during cranial surgery.
- 1 November 2014
- Vol. 25, 265-70
(EVICEL) for Augmentation of Dural Closure: Results of a Preliminary Clinical Study.
The authors prospectively evaluated the safety and efficacy of a new fibrin sealant in patients undergoing emergency and elective cranial/spinal surgery with documented cerebrospinal fluid (CSF) leakage after sutured dural repair. This study was designed as a prospective, nonrandomized clinical trial. EVICEL® Fibrin Sealant (Johnson & Johnson, Somerville, NJ) was used in 72 patients with documented intraoperative CSF leakage after neurosurgical dural repair for a variety of pathologies. Intraoperative CSF leakage was either spontaneous or induced by a Valsalva maneuver. Patients were monitored for 1 month postoperatively with physical examinations, clinical laboratory analyses, and diagnostic imaging (CT or MRI). The sealant was effective in closing intraoperative CSF leakage in all patients but one. There were no sealant-related adverse events, and all clinical outcomes were consistent with expectations for seriously ill patients undergoing prolonged neurosurgical procedures. EVICEL® Fibrin Sealant provides a safe and effective watertight closure when used as an adjunct to sutured dural repair during cranial surgery.
- 1 November 2014
- Vol. 25, 280-5
Use of a Thrombin-gelatin Hemostatic Matrix (Surgiflo) in Spinal Surgery.
A variety of techniques have been used to stop venous bleeding from the spinal epidural space. These generally consist of packing with Surgicel®, fibrillar collagen or Gelfoam®. Bipolar coagulation may also be used to control bleeding from spinal venous plexus, but it may bear the risk of healthy nervous tissue injury: dissipation of heat from the tips of the bipolar forceps may induce thermal injury to adjacent neural structures. In the case of intraspinal bleeding, quick and safe hemostasis is mandatory to ensure adequate visualization and safe preparation so as to avoid damaging nerves and spinal medulla. In addition, quick and safe hemostasis reduces the duration of surgery. Efficient control of bleeding can thereby reduce perioperative morbidity. During 6 months, the authors performed more than 170 major spinal surgeries, and in 67 procedures they used injection of thrombin-gelatin hemostatic matrix (Surgiflo, Johnson & Johnson Wound Management, Somerville, NJ) into spinal epidural space to assist in hemostasis. When the venous bleeding continued from the epidural space after packing with hemostatic agents as Surgicel and fibrillar collagen, gelatin matrix was used to stop venous bleeding. In all cases, the results were judged to be excellent, with immediate stoppage of epidural bleeding, or good. No complications related to the thrombin-gelatin hemostatic matrix were encountered. The thrombin-gelatin matrix could represent a valuable tool when other hemostatic strategies are ineffective or suboptimal. It is safe and biocompatible when compared with hemostatic agents currently in use. This is the first study reporting the use of Surgiflo hemostatic matrix in spinal surgery.
- 1 November 2014
- Vol. 25, 280-5
Use of a Thrombin-gelatin Hemostatic Matrix (Surgiflo) in Spinal Surgery.
A variety of techniques have been used to stop venous bleeding from the spinal epidural space. These generally consist of packing with Surgicel®, fibrillar collagen or Gelfoam®. Bipolar coagulation may also be used to control bleeding from spinal venous plexus, but it may bear the risk of healthy nervous tissue injury: dissipation of heat from the tips of the bipolar forceps may induce thermal injury to adjacent neural structures. In the case of intraspinal bleeding, quick and safe hemostasis is mandatory to ensure adequate visualization and safe preparation so as to avoid damaging nerves and spinal medulla. In addition, quick and safe hemostasis reduces the duration of surgery. Efficient control of bleeding can thereby reduce perioperative morbidity. During 6 months, the authors performed more than 170 major spinal surgeries, and in 67 procedures they used injection of thrombin-gelatin hemostatic matrix (Surgiflo, Johnson & Johnson Wound Management, Somerville, NJ) into spinal epidural space to assist in hemostasis. When the venous bleeding continued from the epidural space after packing with hemostatic agents as Surgicel and fibrillar collagen, gelatin matrix was used to stop venous bleeding. In all cases, the results were judged to be excellent, with immediate stoppage of epidural bleeding, or good. No complications related to the thrombin-gelatin hemostatic matrix were encountered. The thrombin-gelatin matrix could represent a valuable tool when other hemostatic strategies are ineffective or suboptimal. It is safe and biocompatible when compared with hemostatic agents currently in use. This is the first study reporting the use of Surgiflo hemostatic matrix in spinal surgery.
- 1 September 2013
- Vol. 23, 296-306
Safety of intraoperative electrophysiological monitoring (TES and EMG) for spinal and cranial lesions.
Intraoperative motor evoked potentials (MEP) and electromyography (EMG) monitoring in patients with spinal and cranial lesions is a valuable tool for prevention of postoperative motor deficits. The purpose of this study was to determine whether electrophysiological monitoring during skull base, spinal cord, and spinal surgery might be useful for predicting postoperative motor deterioration. From January 2012 to March 2013, thirty-three consecutive patients were studied using intraoperative monitoring (Nuvasive NV-M5 System) to check the integrity of brainstem, spinal cord, and nerve roots, recording transcranial motor evoked potentials (TcMEPs) and electromyography. Changes in MEPs and EMGs were related to postoperative deficits. Preoperative diagnosis included skull base and brainstem lesions (6 patients), spinal tumors (11 patients), spinal deformity (16 cases). Using TcMEPs and EMG is a practicable and safe method. MEPs are useful in any surgery in which the brainstem and spinal cord are at risk. EMG stimulation helps to identify an optimal trans-psoas entry point for an extreme lateral lumbar interbody fusion (XLIF) approach to protect against potential nerve injury. This neural navigation technique via a surgeon-interpreted interface assists the surgical team in safely removing lesions and accessing the intervertebral disc space for minimally invasive spinal procedures.
- 1 September 2013
- Vol. 23, 296-306
Safety of intraoperative electrophysiological monitoring (TES and EMG) for spinal and cranial lesions.
Intraoperative motor evoked potentials (MEP) and electromyography (EMG) monitoring in patients with spinal and cranial lesions is a valuable tool for prevention of postoperative motor deficits. The purpose of this study was to determine whether electrophysiological monitoring during skull base, spinal cord, and spinal surgery might be useful for predicting postoperative motor deterioration. From January 2012 to March 2013, thirty-three consecutive patients were studied using intraoperative monitoring (Nuvasive NV-M5 System) to check the integrity of brainstem, spinal cord, and nerve roots, recording transcranial motor evoked potentials (TcMEPs) and electromyography. Changes in MEPs and EMGs were related to postoperative deficits. Preoperative diagnosis included skull base and brainstem lesions (6 patients), spinal tumors (11 patients), spinal deformity (16 cases). Using TcMEPs and EMG is a practicable and safe method. MEPs are useful in any surgery in which the brainstem and spinal cord are at risk. EMG stimulation helps to identify an optimal trans-psoas entry point for an extreme lateral lumbar interbody fusion (XLIF) approach to protect against potential nerve injury. This neural navigation technique via a surgeon-interpreted interface assists the surgical team in safely removing lesions and accessing the intervertebral disc space for minimally invasive spinal procedures.